Kronik Hepatit C Genotip 1 de Güncel Tedavi

Hepatit C virüsü (HCV) hem akut, hem de kronik hepatite sebep olur. Akut enfeksiyondan sonra hastaların yaklaşık %80’inde kronik enfeksiyon gelişir. Kronik hepatit C (KHC) yıllar içinde ilerleyici bir seyir izleyerek siroz, hepatosellüler karsinom (HCC) veya karaciğer transplantasyonu ile sonuçlanabilir. Dünyada karaciğer transplantasyonunun en sık nedenleri arasında yer alır. Son zamanlarda KHC tedavisinde veren baş döndürücü gelişmeler olmuştur. Yeni gelişmelerle %90 -95 in üzerinde başarı oranı sağlanmış olması gelecek için ümit vericidir.

Current Treatment of Chronic Hepatitis C Genotype 1

Hepatitis C virus (HCV) causes both acute and chronic hepatitis. Following acute HCV infection, chronic infection develops in about %80 of patients. In years, Chronic hepatitis C(CHC) can progress to cirrhosis, hepatocellular carcinoma (HCC) or may result in liver transplantation. It is one of the most common causes of liver transplantion in the world. Recently, the treatment of CHC has dramatically improved. The success rate of over 90-95% with new developments in treatment, is promising for the future.

Kaynakça

He L F, Alling D, Popkin T et al. Determining the size of nonA non-B hepatitis by filtration. JInfect Dis 1987 ;156:636-640

Papatheodoridis G, Hatzakis A. Public health issues of hepatitis C virus infection. Best Pract Res Clin Gastroenterol 2012;26:371-80.

3-Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4): 1333-42.

Manns MP, McHutchson JG, Gordon SC et al.PEGPEG-interferon Alfa-2B plus ribavirin compared to interferon Alfa-2B plus Ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65

Lawitz E1, Poordad FF2, Pang PS et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial: Lancet. 2014 Feb 8;383(9916):515-23. doi: 10.1016/S0140-6736(13)62121-2. Epub 2013 Nov 5.

Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889.

Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383:515.

Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146:736.

Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594.

Poordad F, Hezode C, Trinh R, et al. ABT-450/rombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973.

Ferenci P, Bernstein D, Lalezari J, et al. ABT- 450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983.

Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatmentnaive patients: the COSMOS randomised study. Lancet 2014; 384:1756.

Pearlman BL, Ehleben C, Perrys M. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis. Gastroenterology 2015; 148:762.

Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. January 2014 http://www.hcvguidelines.org/ (Accessed on January 01, 2015).

European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63:199.

Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483.

Poordad F, Hezode C, Trinh R, et al. ABT-450/rombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973.

Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1604.

Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatmentexperienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147:359.

Bourlière M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, doubleblind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15:397.

Reddy KR, Bourlière M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology 2015; 62:79.

Osinusi A, Kohli A, Marti MM, et al. Retreatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med 2014; 161:634.

Wyles D, Pockros P, Morelli G, et al. Ledipasvirsofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 2015; 61:1793.

Kaynak Göster

Van Tıp Dergisi
  • ISSN: 1300-2694
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1994

2b447

Sayıdaki Diğer Makaleler

Clinical Features of a Pediatric Case with Cone Dystrophy

LOKMAN BALYEN, Tuncay KÜSBECİ

Radiokarpal Ekleme Enjeksiyonda Palpasyon ile Enjeksiyonun Ultrasonografi Eşliğinde Enjeksiyon ile Karşılaştırılması

GÖKHAN POLAT, AHMET YALÇIN

Deneysel Pnömoperitonyumun Pıhtılaşma Değişkenleri Üzerine Olan Etkilerinin Tromboelastografi Yöntemi ile Değerlendirilmesi

HALİT ZİYA DÜNDAR, Ömer ARAN

Periodontal Klinik Parametreler ile Ağız Sağlığına Bağlı Yaşam Kalitesi Arasındaki İlişkinin Değerlendirilmesi

HACER ŞAHİN AYDINYURT, Dicle ALTINDAL

Bariatrik Cerrahi Sonrasında Morbid Obez ve Süper Obezlerdeki Pulmoner Fonksiyonların Karşılaştırılması

BURCU YORMAZ, İlhan ECE, BAYRAM ÇOLAK, Serdar YORMAZ, Hilmi DEMİRKIRAN

Bir Çocuk Psikiyatri Ayaktan Tedavi Ünitesine Başvuran Çocuk ve Ergenlerde Gözlenen Psikiyatrik Bozuklukların Değerlendirilmesi

VEYSİ ÇERİ, ÜRÜN ÖZER ÇERİ, MEHMET EMİN LAYIK, Fatma Betül Ay İZ

Akut Gastroenteritli Çocuk Hastalarda Rotavirüs Enfeksiyonu Sıklığı

Serhat SAMANCI, Muhammet KÖŞKER, Muhittin ÇELİK, EŞREF ARAÇ

Van İlindeki Bir Üniversite Hastanesinin El Cerrahisi Kliniğine Başvuran Hastalarin Profili

Hasan Onur ARIK, Tamer COŞKUN

An Overlook on Diffusion Mr of Stroke Patients

Serkan KOCKANAT

Aort Kapak Replasmanı Yapılan 70 Yaş Üstü Hastalarda Mekanik İle Biyoprotez Kapağın Karşılaştırılması: Mekanik&Biyoprotez Aort Kapak

Safa GÖDE, OZAN ONUR BALKANAY, DENİZ GÖKSEDEF, SUAT NAİL ÖMEROĞLU, GÖKHAN İPEK